Welcome to our dedicated page for Milestone Scient news (Ticker: MLSS), a resource for investors and traders seeking the latest updates and insights on Milestone Scient stock.
Milestone Scient (MLSS) delivers innovative computer-controlled anesthetic systems designed to improve patient comfort in dental and medical procedures. This dedicated news hub provides real-time updates on the company’s technological advancements, regulatory milestones, and strategic partnerships.
Access authoritative information on MLSS’s global expansion across 25+ countries, product innovations like the CompuDent and CompuMed systems, and financial performance. The curated content serves investors and healthcare professionals seeking to monitor the company’s impact on pain management technology.
Key updates include FDA clearances, clinical trial results, partnership announcements with medical institutions, and market penetration strategies. All content is sourced directly from official company communications to ensure accuracy and timeliness.
Bookmark this page for streamlined access to MLSS’s latest developments, enabling data-driven insights into its role in advancing precision anesthetic delivery worldwide.
Milestone Scientific (NYSE: MLSS) reported a remarkable 90% year-over-year revenue growth for 2021, totaling $10.3 million, surpassing previous guidance and pre-pandemic levels. The company highlights strong dental division performance and profitability with high gross margins. Expansion in medical distribution includes new partnerships with pain management clinics and hospitals. Despite challenges from the pandemic, particularly in labor and delivery departments, Milestone is optimistic about regaining momentum. The company holds a robust cash position of $14.8 million to fuel growth initiatives.
Milestone Scientific (NYSE:MLSS) has announced a conference call set for April 1, 2022, at 8:30 AM ET to discuss its financial results for the fiscal year ending December 31, 2021. The call will cover corporate progress and developments. Investors can join via telephone or access a webcast on the company’s Investor Relations page. An audio replay will be available until April 15, 2022. Milestone Scientific specializes in computerized drug delivery instruments aimed at providing painless and precise injections, enhancing patient comfort and safety.
Milestone Scientific (NYSE:MLSS) has launched sales of its CompuFlo Epidural disposables at two California surgery centers: Cypress and Galileo. Both facilities, owned by Pain Management Specialists, will utilize Milestone's technology to enhance patient care. CEO Arjan Haverhals noted that this expansion follows successful evaluations of the system's safety and economic efficiency. Milestone is focused on developing advanced drug delivery systems to improve injection precision, comfort, and safety.
Milestone Scientific Inc. (NYSE: MLSS) is set to participate in The MicroCap Rodeo’s 2nd Annual Winter Wonderland Best Ideas Conference from February 8-11, 2022. CEO Arjan Haverhals will present on February 9 at 10:30 AM ET. The presentation can be accessed via webcast on the company's website. The conference includes 25-minute virtual presentations and one-on-one meetings for investors. This event showcases qualified institutional investors' best ideas.
Milestone Scientific (NYSE: MLSS) announced that CEO Arjan Haverhals will participate in a virtual fireside chat on January 20, 2022, hosted by Maxim Group's Anthony Vendetti. This event aims to provide insights into Milestone's advanced computerized drug delivery technology, which ensures painless and precise injections. Investors can view the live webcast at 11:00 a.m. EST, with a replay available for 48 hours afterward. Milestone is focused on enhancing patient comfort and safety through its innovative DPS Dynamic Pressure Sensing Technology®.
Milestone Scientific (NYSE: MLSS) reports anticipated revenues over $2.6 million for Q4 2021, up from $2.2 million in Q4 2020, and over $10 million for FY 2021, a significant increase from $5.4 million in FY 2020. CEO Arjan Haverhals highlights growth in dental and medical divisions, with successful marketing efforts and new distributors contributing to an 85% revenue increase. The company expresses confidence in its future, citing a strong balance sheet and a substantial market opportunity in the U.S. for epidural analgesia, estimated at over $5 billion annually.
Milestone Scientific (NYSE:MLSS) recently announced that CEO Arjan Haverhals will present at the H.C. Wainwright BioConnect 2022 Conference, which occurs virtually from January 10-13, 2022. The presentation will be available on-demand starting January 10 at 7:00 AM Eastern Time for registered attendees. Milestone Scientific specializes in developing computerized drug delivery instruments aimed at providing painless injections, enhancing patient comfort and safety through innovative DPS Dynamic Pressure Sensing Technology.
Milestone Scientific (NYSE:MLSS) has expanded into the pain management market with the incorporation of the CompuFlo Epidural instrument by Dr. Harsh Govil in his practice in Statesville, NC. This decision follows a successful evaluation and aims to enhance patient safety and efficacy in pain management procedures. Arjan Haverhals, CEO, emphasized the growing traction in this sector, noting over 11 million annual epidural procedures in the U.S. Milestone aims to advance its technology beyond labor and delivery into broader applications in pain management.
Milestone Scientific (NYSE: MLSS) has announced the purchase of CompuFlo Epidural and CathCheck Verification System disposables from two prominent hospitals, enhancing its market presence. CEO Arjan Haverhals highlighted that these orders mark significant progress as both hospitals are part of large healthcare systems. The technology reportedly improves safety, efficiency, and offers economic advantages. Published studies support the technology's effectiveness, potentially reducing costs and complication rates associated with procedures.
Milestone Scientific (NYSE:MLSS) has announced a new agreement with Andau Medical to distribute its STA Single Tooth Anesthesia System in the U.S. and Canada. This partnership aims to enhance the dental experience by providing painless injections, reducing wait times, and minimizing complications. CEO Arjan Haverhals expressed optimism about the collaboration, noting Andau's strong track record in the dental market. Andau Medical’s founder, Sandi Wright, highlighted the system’s benefits for both patients and clinicians.
FAQ
What is the current stock price of Milestone Scient (MLSS)?
What is the market cap of Milestone Scient (MLSS)?
